20/20 Biolabs (NASDAQ:AIDX) Announces Quarterly Earnings Results

20/20 Biolabs (NASDAQ:AIDX) released its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.35 million for the quarter.

20/20 Biolabs Price Performance

NASDAQ:AIDX traded down $0.05 during trading hours on Wednesday, hitting $1.29. The stock had a trading volume of 35,968 shares, compared to its average volume of 227,330. The business’s 50 day moving average price is $1.80. 20/20 Biolabs has a one year low of $1.26 and a one year high of $50.00.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AIDX shares. Wall Street Zen upgraded 20/20 Biolabs to a “hold” rating in a research report on Saturday, March 14th. Maxim Group began coverage on 20/20 Biolabs in a research note on Monday, May 11th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Weiss Ratings initiated coverage on 20/20 Biolabs in a research note on Thursday, May 14th. They issued a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.